Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Prutch, Zachary
NCT05481151: A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV Feb 2024 - Dec 2024 : Topline data for adults with PV	Active, not recruiting	3	111	Canada, US	P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)	PharmaEssentia	Polycythemia Vera	12/24	07/25
EXCEED ET, NCT05482971: A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET	Active, not recruiting	2	91	Canada, US	Ropeginterferon alfa-2b-njft (P1101), P1101	PharmaEssentia	Essential Thrombocythemia	03/27	03/27
Jessup, Jewell
NCT05481151: A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV Feb 2024 - Dec 2024 : Topline data for adults with PV	Active, not recruiting	3	111	Canada, US	P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)	PharmaEssentia	Polycythemia Vera	12/24	07/25
EXCEED ET, NCT05482971: A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET	Active, not recruiting	2	91	Canada, US	Ropeginterferon alfa-2b-njft (P1101), P1101	PharmaEssentia	Essential Thrombocythemia	03/27	03/27